Top

Published in:

01-03-2020 | Nephrectomy | Original Paper

Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities

Authors: Stefano Luzzago, Carlotta Palumbo, Giuseppe Rosiello, Sophie Knipper, Angela Pecoraro, Sebastiano Nazzani, Zhe Tian, Gennaro Musi, Emanuele Montanari, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Ottavio de Cobelli, Pierre I. Karakiewicz

Published in: Cancer Causes & Control | Issue 3/2020

Abstract

Purpose

To test the association between African-American race and overall mortality (OM) rates in patients with metastatic renal cell carcinoma (mRCC).

Methods

Within the Surveillance, Epidemiology, and End Results registry (2006–2015), we identified patients with clear cell (ccmRCC) and non-clear cell mRCC (non-ccmRCC). African-Americans, Caucasians, and Hispanics were identified. Stratification was made according to histology and treatments: (1) no treatment, (2) systemic therapy (ST), (3) cytoreductive nephrectomy (CNT), (4) CNT + ST. Kaplan–Meier plots and multivariable Cox regression analyses were used.

Results

Of ccmRCC patients, 410 (7%), 4353 (75%), and 1005 (17%) were African-American, Caucasian, and Hispanic, respectively. Of non-ccmRCC patients, 183 (25%), 479 (65%), and 77 (10%) were African-American, Caucasian, and Hispanic, respectively. In ccmRCC, African-Americans were associated with higher OM rates (HR 1.20; 95% CI 1.05–1.37). Conversely, in non-ccmRCC, African-Americans were associated with lower OM rates (HR 0.75; 95% CI 0.59–0.97).

Conclusion

African-American race is associated with prolonged survival in non-ccmRCC, but it is also associated with lower survival rates in ccmRCC. The exception to these observations consisted of patients treated with combination of CNT + ST for either ccmRCC or non-ccmRCC.

Available only for authorised users

Capitanio U, Montorsi F (2016) Seminar renal cancer. Lancet. https://doi.org/10.1016/S0140-6736(15)00046-X CrossRefPubMed

Vaishampayan UN, Do H, Hussain M, Schwartz K (2003) Racial disparity in incidence patterns and outcome of kidney cancer. Urology 62:1012–1017. https://doi.org/10.1016/j.urology.2003.07.010 CrossRefPubMed

Stafford HS, Saltzstein SL, Shimasaki S et al (2008) Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 179:1704–1708. https://doi.org/10.1016/j.juro.2008.01.027 CrossRefPubMedPubMedCentral

Chow W-H, Shuch B, Linehan WM, Devesa SS (2012) Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer 119:388–394. https://doi.org/10.1002/cncr.27690 CrossRefPubMedPubMedCentral

Schwartz K, Ruterbusch JJ, Colt JS et al (2016) Racial disparities in overall survival among renal cell carcinoma patients with young age and small tumors. Cancer Med 5:200–208. https://doi.org/10.1002/cam4.578 CrossRefPubMed

Zini L, Perrotte P, Capitanio U et al (2009) Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU Int 103:889–893. https://doi.org/10.1111/j.1464-410X.2008.08119.x CrossRefPubMed

Becker A, Roghmann F, Trinh QD et al (2013) Sociodemographic disparities in the treatment of small renal masses. BJU Int 111:274–282. https://doi.org/10.1111/bju.12111 CrossRef

Berndt SI, Carter HB, Schoenberg MP, Newschaffer CJ (2007) Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol 25:3589–3595. https://doi.org/10.1200/JCO.2006.10.0156 CrossRefPubMed

Cote ML, Colt JS, Schwartz KL et al (2012) Cigarette smoking and renal cell carcinoma risk among black and white Americans: effect Modification by Hypertension and Obesity. Cancer Epidemiol Biomarkers Prev 21:770–779. https://doi.org/10.1158/1055-9965.EPI-11-1109 CrossRefPubMedPubMedCentral

10.

Colt JS, Schwartz K, Graubard BI et al (2011) Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 22:797–804. https://doi.org/10.1097/EDE.0b013e3182300720 CrossRefPubMedPubMedCentral

11.

Hofmann JN, Schwartz K, Chow WH et al (2013) The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans. Cancer Causes Control 24:167–174. https://doi.org/10.1007/s10552-012-0102-z CrossRefPubMed

12.

Beebe-Dimmer JL, Colt JS, Ruterbusch JJ et al (2012) Body mass index and renal cell cancer. Epidemiology 23:821–828. https://doi.org/10.1097/ede.0b013e31826b7fe9 CrossRefPubMedPubMedCentral

13.

Tripathi RT, Heilbrun LK, Jain V, Vaishampayan UN (2006) Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma. Urology 68:296–301. https://doi.org/10.1016/j.urology.2006.02.036 CrossRefPubMed

14.

Rose TL, Deal AM, Krishnan B et al (2016) Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era. Cancer 122:2988–2995. https://doi.org/10.1002/cncr.30146 CrossRefPubMedPubMedCentral

15.

Vaishampayan U, Vankayala H, Vigneau FD et al (2014) The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database. Clin Genitourin Cancer 12:124–129. https://doi.org/10.1016/j.clgc.2013.09.007 CrossRefPubMed

16.

Marchioni M, Harmouch SS, Nazzani S et al (2018) Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. Cancer Epidemiol 54:112–118. https://doi.org/10.1016/j.canep.2018.04.006 CrossRefPubMed

17.

Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ (eds) (2018) Cancer statistics review, 1975–2015—seer statistics. Natl. Cancer Institute, Bethesda

18.

Sun M, Abdollah F, Liberman D et al (2011) Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis. Cancer. https://doi.org/10.1002/cncr.25969 CrossRefPubMedPubMedCentral

19.

Lipworth L, Morgans AK, Edwards TL et al (2016) Renal cell cancer histological subtype distribution differs by race and sex. BJU Int 117:260–265. https://doi.org/10.1111/bju.12950 CrossRefPubMed

20.

Olshan AF, Kuo TM, Meyer AM et al (2013) Racial difference in histologic subtype of renal cell carcinoma. Cancer Med 2:744–749. https://doi.org/10.1002/cam4.110 CrossRefPubMedPubMedCentral

21.

Qi P, Tsivian M, Abern MR et al (2014) Clinicopathological characteristics and outcomes of surgically excised renal masses in African Americans. Urol Oncol Semin Orig Investig 32:555–560. https://doi.org/10.1016/j.urolonc.2013.11.011 CrossRef

22.

Lipworth L, Tarone RE, McLaughlin JK (2011) Renal cell cancer among African Americans: an epidemiologic review. BMC Cancer. https://doi.org/10.1186/1471-2407-11-133 CrossRefPubMedPubMedCentral

23.

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin. https://doi.org/10.3322/caac.21551 CrossRefPubMed

24.

Goodwin JS, Hunt WC, Key CR, Samet JM (1987) The effect of marital status on stage, treatment, and survival of cancer patients. JAMA J Am Med Assoc. https://doi.org/10.1001/jama.1987.03400210067027 CrossRef

25.

Hellenthal NJ, Chamie K, Ramirez ML, deVere White RW (2009) Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma. J Urol. https://doi.org/10.1016/j.juro.2008.10.159 CrossRefPubMed

26.

Krishnan B, Rose TL, Kardos J et al (2016) Intrinsic genomic differences between african American and white patients with clear cell renal cell carcinoma. JAMA Oncol 2:664–667. https://doi.org/10.1001/jamaoncol.2016.0005 CrossRefPubMed

27.

Paulucci DJ, Sfakianos JP, Skanderup AJ et al. (2016) Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma. Oncotarget 8:5196–5205. 10.18632/oncotarget.14122.

28.

Kaldany A, Blum KA, Paulucci DJ et al (2018) An evaluation of race, ethnicity, age, and sex-based representation in phase I to II renal cell carcinoma clinical trials in the United States. Urol Oncol Semin Orig Investig 36:363.e1–363.e6. https://doi.org/10.1016/j.urolonc.2018.05.006 CrossRef

29.

Sun M, De Velasco G, Brastianos PK et al (2018) The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.12.007 CrossRefPubMed

30.

Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. https://doi.org/10.1200/JCO.2008.21.4809 CrossRefPubMed

31.

Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. https://doi.org/10.1200/JCO.20.1.289 CrossRefPubMed

32.

Vera-Badillo FE, Templeton AJ, Duran I et al (2015) Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur, Urol

Title: Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities
Authors: Stefano Luzzago
Carlotta Palumbo
Giuseppe Rosiello
Sophie Knipper
Angela Pecoraro
Sebastiano Nazzani
Zhe Tian
Gennaro Musi
Emanuele Montanari
Shahrokh F. Shariat
Fred Saad
Alberto Briganti
Ottavio de Cobelli
Pierre I. Karakiewicz
Publication date: 01-03-2020
Publisher: Springer International Publishing
Keywords: Nephrectomy
Kidney Cancer
Kidney Cancer
Systemic Therapy
Nephrectomy
Kidney Cancer
Nephrectomy
Published in: Cancer Causes & Control / Issue 3/2020
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-020-01270-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Rural–urban disparities in colorectal cancer survival and risk among men in Utah: a statewide population-based study

The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages

Comorbidity and stage at diagnosis among lung cancer patients in the US military health system

Patient- and area-level predictors of prostate cancer among South Carolina veterans: a spatial analysis

Allergy, asthma, and the risk of breast and prostate cancer: a Mendelian randomization study

Childhood leukaemia incidence and trends in a Middle Eastern country during 1980–2014: a population-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer